bpc 157 human studies randomized clinical trial Multifunctionality and Possible Medical Application of the Peptide—Literature and Patent Review Christopher Mendias, PhD, gets four
Description
In combination protocols, GHK-Cu is typically administered via subcutaneous injection at doses of 200 to 600 mcg daily
Link United States Anti-Doping Agency (USADA)
Full therapeutic doses are a separate and more promising story, now in trials for depression and, as covered above, in an early test in Parkinsons
AE profile
